[go: up one dir, main page]

WO2025091269A1 - Utilisation de lactobacillus gasseri tf08-1 dans la prévention et le traitement d'une infection par helicobacter pylori - Google Patents

Utilisation de lactobacillus gasseri tf08-1 dans la prévention et le traitement d'une infection par helicobacter pylori Download PDF

Info

Publication number
WO2025091269A1
WO2025091269A1 PCT/CN2023/128658 CN2023128658W WO2025091269A1 WO 2025091269 A1 WO2025091269 A1 WO 2025091269A1 CN 2023128658 W CN2023128658 W CN 2023128658W WO 2025091269 A1 WO2025091269 A1 WO 2025091269A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactobacillus gasseri
helicobacter pylori
inflammatory
cfu
postbiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2023/128658
Other languages
English (en)
Chinese (zh)
Inventor
钟一祎
罗强
张海峰
邹远强
肖亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bgi Precision Nutrition (shenzhen) Technology Co Ltd
BGI Shenzhen Co Ltd
Original Assignee
Bgi Precision Nutrition (shenzhen) Technology Co Ltd
BGI Shenzhen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bgi Precision Nutrition (shenzhen) Technology Co Ltd, BGI Shenzhen Co Ltd filed Critical Bgi Precision Nutrition (shenzhen) Technology Co Ltd
Priority to PCT/CN2023/128658 priority Critical patent/WO2025091269A1/fr
Publication of WO2025091269A1 publication Critical patent/WO2025091269A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Definitions

  • the invention relates to the technical field of microorganisms, and in particular to application of Lactobacillus gasseri in preventing and treating Helicobacter pylori infection.
  • Hp Helicobacter pylori
  • Hp has been listed as a Class I biological carcinogen by the World Health Organization in 2022.
  • Hp-infected people have no obvious symptoms in the early stage, and some may have symptoms of acute gastritis, including upper abdominal pain, abdominal distension, belching, nausea and vomiting, and loss of appetite, but almost all patients will have varying degrees of chronic active gastritis symptoms, and once infected with Hp, it is extremely difficult to heal on its own, and the infected person will suffer for life.
  • the transmission routes of Hp include oral-oral and fecal-oral transmission, and group cluster infections often occur. Studies have shown that the infection rate of Helicobacter pylori in my country is as high as 56%. Due to its mild symptoms, it is often ignored by patients and not promptly eradicated and treated.
  • the diagnosis of Helicobacter pylori mainly includes urea breath test (UBT), fecal Helicobacter pylori antigen test (HpSA), Helicobacter pylori serological antibody test and histological examination. Timely examination and eradication treatment are important intervention measures to avoid the progression of the disease.
  • Patent US6596530B1 discloses that Lactobacillus gasseri OLL2716 can grow under low pH conditions and achieve a 90.5% antibacterial rate after 48 hours of mixed culture with Helicobacter pylori.
  • the current antibacterial ability of Lactobacillus gasseri is insufficient, and there is also a lack of a method for preventing Helicobacter pylori infection.
  • live bacteria are inconvenient to store and transport, making it difficult to expand their scope of application.
  • the technical problem to be solved by the present invention is that the existing Lactobacillus gasseri has insufficient antibacterial ability and lacks a method for preventing Helicobacter pylori infection.
  • an active probiotic product which comprises a bacterial liquid or bacterial powder of Lactobacillus gasseri; wherein the Lactobacillus gasseri is Lactobacillus gasseri TF08-1, and its deposit number is GDMCC60092; when it is a bacterial liquid, the content of the Lactobacillus gasseri is at least 1.0 ⁇ 10 8 CFU/mL; when it is a bacterial powder, the content of the Lactobacillus gasseri is at least 1.0 ⁇ 10 9 CFU/g.
  • the content of Lactobacillus gasseri of at least 1.0 ⁇ 10 8 CFU/mL means that it can be 1.0 ⁇ 10 8 CFU/mL, 2.0 ⁇ 10 8 CFU/mL, 3.0 ⁇ 10 8 CFU/mL, 4.0 ⁇ 10 8 CFU/mL, 5.0 ⁇ 10 8 CFU/mL, 6.0 ⁇ 10 8 CFU/mL, 7.0 ⁇ 10 8 CFU/mL, 8.0 ⁇ 10 8 CFU/mL, 9.0 ⁇ 10 8 CFU/mL, 1.0 ⁇ 10 9 CFU/mL, 2.0 ⁇ 10 9 CFU/mL, 5.0 ⁇ 10 9 CFU/mL, 1.0 ⁇ 10 10 CFU/mL, 2.0 ⁇ 10 10 CFU/mL, 5.0 ⁇ 10 10 CFU/mL, 1 CFU/mL and the like, and an appropriate concentration can be determined in the art based on 1.0 ⁇ 10 8 CFU/mL.
  • the content of Lactobacillus gasseri may be 1.0 ⁇ 10 8 -1.0 ⁇ 10 11 CFU/mL, for example, 1.0 ⁇ 10 8 -1.0 ⁇ 10 9 CFU/mL, 1.0 ⁇ 10 9 -1.0 ⁇ 10 10 CFU/mL, 1.0 ⁇ 10 10 -1.0 ⁇ 10 11 CFU/mL; 5.0 ⁇ 10 8 -5.0 ⁇ 10 9 CFU/mL, 5.0 ⁇ 10 9 -5.0 ⁇ 10 10 CFU/mL, 5.0 ⁇ 10 10 -1.0 ⁇ 10 11 CFU/mL, etc.
  • the content of Lactobacillus gasseri of at least 1.0 ⁇ 10 9 CFU/g means that it can be 1.0 ⁇ 10 9 CFU/g, 2.0 ⁇ 10 9 CFU/g, 3.0 ⁇ 10 9 CFU/g, 4.0 ⁇ 10 9 CFU/g, 5.0 ⁇ 10 9 CFU/g, 6.0 ⁇ 10 9 CFU/g, 7.0 ⁇ 10 9 CFU/g, 9.0 ⁇ 10 9 CFU/g, 10.0 ⁇ 10 9 CFU/g, 1.0 ⁇ 10 10 CFU/g, 2.0 ⁇ 10 10 CFU/g, 5.0 ⁇ 10 10 CFU/g, 1.0 ⁇ 10 11 CFU/g, 2.0 ⁇ 10 11 CFU/g, 5.0 ⁇ 10 11 CFU/g, 1.0 ⁇ 10 12 CFU/g, 12 CFU/g, etc.
  • the appropriate concentration can be determined in the art based on 1.0 ⁇ 10 9 CFU/g.
  • the content of Lactobacillus gasseri may be 1.0 ⁇ 10 9 -1.0 ⁇ 10 12 CFU/g, for example, 1.0 ⁇ 10 9 -1.0 ⁇ 10 10 CFU/g, 1.0 ⁇ 10 10 -1.0 ⁇ 10 11 CFU/g, 1.0 ⁇ 10 11 -1.0 ⁇ 10 12 CFU/g; 5.0 ⁇ 10 9 -5.0 ⁇ 10 10 CFU/g, 5.0 ⁇ 10 10 -5.0 ⁇ 10 11 CFU/g, 5.0 ⁇ 10 11 -1.0 ⁇ 10 12 CFU/g, etc.
  • a postbiotic product is provided, which is prepared by inactivating the active probiotic product described in the first aspect.
  • the postbiotic product is prepared by heating and inactivating the active probiotic product described in the first aspect at 63-65° C. for 30 minutes.
  • a Lactobacillus gasseri the active probiotic product described in the first aspect or the postbiotic product described in the second aspect, which is used for preparing a preparation for preventing and/or treating a disease caused by Helicobacter pylori infection; wherein the Lactobacillus gasseri is Lactobacillus gasseri TF08-1, and its deposit number is GDMCC60092.
  • the disease caused by Helicobacter pylori infection is a gastrointestinal disease or an inflammatory response.
  • the gastrointestinal disease or inflammatory response is systemic inflammatory response syndrome, gastritis, gastric tissue damage or gastric mucosal atrophy; the gastritis is, for example, acute gastritis or chronic gastritis.
  • a Lactobacillus gasseri the active probiotic product described in the first aspect or the postbiotic product described in the second aspect is provided, which is used to regulate the levels of serum anti-inflammatory factors and/or serum pro-inflammatory factors; wherein the Lactobacillus gasseri is Lactobacillus gasseri TF08-1, and its deposit number is GDMCC60092.
  • the serum anti-inflammatory factor is IL-10; the serum pro-inflammatory factor is TNF- ⁇ , IL-1 ⁇ or IL-6.
  • a Lactobacillus gasseri the active probiotic product according to the first aspect or the postbiotic product according to the second aspect, which is used to inhibit urease activity; wherein the Lactobacillus gasseri is Lactobacillus gasseri TF08-1, and its deposit number is GDMCC60092.
  • the urease is urease produced by Helicobacter pylori.
  • a method for inhibiting the activity of Helicobacter pylori or urease comprising adding Lactobacillus gasseri, the active probiotic preparation described in the first aspect, or the postbiotic preparation described in the second aspect to Helicobacter pylori or a sample containing Helicobacter pylori and/or urease; wherein the Lactobacillus gasseri is Lactobacillus gasseri TF08-1, and its preservation number is GDMCC60092.
  • the urease is urease produced by Helicobacter pylori.
  • the methods are for non-diagnostic and/or non-therapeutic purposes.
  • a method for treating a disease caused by Helicobacter pylori infection comprising administering Lactobacillus gasseri, the active probiotic preparation described in the first aspect, or the postbiotic preparation described in the second aspect to a subject in need; wherein the Lactobacillus gasseri is Lactobacillus gasseri TF08-1, and its deposit number is GDMCC60092.
  • the disease caused by Helicobacter pylori infection is a gastrointestinal disease or an inflammatory response.
  • the gastrointestinal disease or inflammatory response is systemic inflammatory response syndrome, gastritis, gastric tissue damage or gastric mucosal atrophy; the gastritis is, for example, acute gastritis or chronic gastritis.
  • the present invention provides a method for regulating the levels of serum anti-inflammatory factors and/or serum pro-inflammatory factors, the method comprising administering Lactobacillus gasseri, the active probiotic preparation described in the first aspect, or the postbiotic preparation described in the second aspect to a subject or sample in need; wherein the Lactobacillus gasseri is Lactobacillus gasseri TF08-1, and its deposit number is GDMCC60092.
  • the serum anti-inflammatory factor is IL-10; the serum pro-inflammatory factor is TNF- ⁇ , IL-1 ⁇ or IL-6.
  • the method is an in vitro modulation method.
  • the present invention has the following beneficial effects:
  • Lactobacillus gasseri TF08-1 active products or postbiotic products can effectively inhibit Helicobacter pylori and the activity of urease; the use of postbiotics can effectively solve the problems of transportation and storage. This makes the application scenarios more extensive; finally, active Lactobacillus gasseri products or postbiotic products can be used to prevent Helicobacter pylori infection and achieve the effect of nourishing and protecting the stomach.
  • FIG. 1 shows the gastric infection and damage conditions of mice in each group in the prevention experiment of Example 4 of the present application.
  • FIG. 2 shows the serum cytokine levels of mice in each group in the prevention experiment of Example 4 of the present application.
  • FIG3 shows the gastric infection and damage conditions of mice in each group in the treatment experiment of Example 5 of the present application.
  • FIG. 4 shows the serum cytokine levels of mice in each group in the treatment experiment of Example 5 of the present application.
  • Helicobacter pylori is a spiral-shaped bacterium that colonizes the stomach and produces urease that increases the pH in the stomach and protects it from gastric acid in this way.
  • the bacterium is able to penetrate the mucosa and deposit on epithelial cells. This infection activates the body's own immune system, which is not enough to effectively eliminate the infection, but leads to a series of chronic inflammations and diseases such as gastritis or gastric ulcers due to the enhanced immune response.
  • Inflammatory responses within the intestinal mucosa lead to loss of integrity of the epithelial layer and increased permeability.
  • Disruption of the epithelial barrier allows immune cells to access luminal material, and activation of the immune system leads to inflammatory responses and production of inflammatory cytokines, such as chemokines, TNF, and IFN.
  • IFN and TNF lead to disruption of tight junctions, while TNF may cause epithelial cell apoptosis.
  • the associated increase in epithelial barrier permeability further exacerbates the inflammatory process and starts a viscous cycle. When progressing to a chronic process, inflammatory bowel disease may develop.
  • Tumor necrosis factor- ⁇ can inhibit the replication of different influenza viruses and has a strong antiviral effect.
  • the main function of tumor necrosis factor- ⁇ is to regulate the function of immune cells. As an endogenous pyrogen, it can promote fever, cause cell apoptosis, cause sepsis (by inducing the production of IL-1 and IL-6), cause cachexia, induce inflammation, and prevent tumorigenesis and viral replication.
  • the active preparation or postbiotic preparation of Lactobacillus gasseri TF08-1 of the present invention can be used to prevent Helicobacter pylori
  • the active product or postbiotic product of Lactobacillus gasseri TF08-1 of the present invention can effectively prevent Helicobacter pylori infection, so if it is taken before infection, it has a preventive effect that Helicobacter pylori is difficult to be infected, and even if infected, it is easy to cure. Therefore, the active product or postbiotic product of Lactobacillus gasseri TF08-1 of the present invention is also preferably taken daily.
  • the administration time of the active Lactobacillus gasseri TF08-1 preparation or the postbiotic preparation of the present invention is not particularly limited, and may be before or after Helicobacter pylori infection.
  • MRS broth medium peptone 10.0g, beef extract 10.0g, yeast powder 5.0g, glucose 20.0g, sodium acetate 5.0g, diammonium hydrogen citrate 2.0g, Tween-801.0mL, dipotassium hydrogen phosphate 2.0g, magnesium sulfate heptahydrate 0.2g, manganese sulfate heptahydrate 0.05g, distilled water 1000mL.
  • peptone 10.0g beef extract 10.0g
  • yeast powder 5.0g
  • glucose 20.0g sodium acetate 5.0g
  • diammonium hydrogen citrate 2.0g Tween-801.0mL
  • dipotassium hydrogen phosphate 2.0g magnesium sulfate heptahydrate 0.2g
  • manganese sulfate heptahydrate 0.05g distilled water 1000mL.
  • MRS agar medium Based on the formula of MRS broth medium, add 20g/L agar, adjust the pH to 6.2-6.4, and sterilize in an autoclave at 121°C for 15 minutes.
  • GSSA-Hp selective Columbia blood plate 12.0 g of tryptic peptone, 5.0 g of animal tissue protein digest, 3.0 g of yeast extract, 3.0 g of beef extract, 1.0 g of corn starch, 5.0 g of sodium chloride, 15 g of agar, 0.5 mg of polymyxin B, 2 mg of nalidixic acid, 2.5 mg of amphotericin, 200 mg of bacitracin, 6 mg of vancomycin, and 1000 mL of distilled water. After mixing the above components, adjust the pH to 7.2-7.4. The product was prepared by sterilizing at 121°C for 15 min in an autoclave, cooling to 50°C, and adding 70 mL of sterile defibrinated sheep blood.
  • Urea-phenol red solution Dissolve 10 g urea and 0.006 g phenol red, mix well, adjust the solution pH to 6.5, and make up to 50 mL.
  • concentration ratios of urea and phenol red are 20% and 0.012%, respectively.
  • H. pylori ATCC 43504 from the American Type Culture Collection (ATCC).
  • Elisa detection kits such as TNF- ⁇ , IL-1 ⁇ , IL-6 and IL-10 were purchased from Nanjing Jiancheng Biotechnology Co., Ltd., and the bacterial genomic DNA extraction kit (DP302) was purchased from Tiangen Biochemical Technology Beijing Co., Ltd. The rest of the experimental materials and equipment were common consumables and equipment in microbiological laboratories.
  • the fermentation broth is subjected to or not subjected to conventional treatment methods such as spray drying (or freeze drying) to obtain TF08-1 probiotics (live bacteria type products), whose bacterial concentration is 1.0 ⁇ 10 9 CFU/g or 1.0 ⁇ 10 9 CFU/mL; the above-mentioned TF08-1 probiotics (live bacteria type products) are heated and inactivated at 63-65°C for 30 minutes to obtain TF08-1 postbiotics (inactivated bacteria type products), whose bacterial concentration is 1.0 ⁇ 10 9 Cell/g or 1.0 ⁇ 10 9 Cell/mL.
  • spray drying or freeze drying
  • This example aims to determine the antibacterial ability of Lactobacillus gasseri TF08-1 against Helicobacter pylori: After activation, Lactobacillus gasseri TF08-1 was centrifuged at 10,000 rpm for 10 min to remove the bacteria, and TF08-1 cell-free fermentation supernatant (Cell Free Supernatant, CFS) was obtained by filtering through a 0.22 ⁇ m aqueous filter membrane as a test sample. The antibacterial ability of CFS against Helicobacter pylori was determined using a microplate antibacterial method. Force: Helicobacter pylori ATCC43504 strain was inoculated on GSSA-Hp selective Columbia blood agar plate for recovery and culture for 3-4 days.
  • CFS Cell Free Supernatant
  • the Helicobacter pylori inhibition rate was calculated according to the following formula:
  • Helicobacter pylori inhibition rate (%) [(OD control group - OD test group) / OD control group] ⁇ 100
  • the experimental results showed that the control group grew well after culture, while the growth of the experimental group co-cultured with Lactobacillus gasseri TF08-1 cell-free supernatant was inhibited, and its Helicobacter pylori inhibition rate was 92.44 ⁇ 3.51%, showing extremely strong Helicobacter pylori inhibition properties, which suggests that Lactobacillus gasseri TF08-1 has the probiotic potential to inhibit the growth and reproduction of Helicobacter pylori.
  • Urease is one of the important physiological function enzymes of Helicobacter pylori, which can hydrolyze urea in gastric juice into carbon dioxide and ammonia, thereby neutralizing gastric acid and protecting the growth and survival of Helicobacter pylori. Therefore, inhibiting urease is a key target for effectively inhibiting Helicobacter pylori.
  • the test sample of Lactobacillus gasseri TF08-1 was prepared according to the method of Example 2, and its urease inhibition ability against Helicobacter pylori was determined by microplate method: 40 ⁇ L of Helicobacter pylori suspension after adjusting the bacterial concentration was taken, and placed in a 96-well plate with 10 ⁇ L of the test sample, and co-cultured in a microaerobic environment for 48 hours. After the cultivation was completed, 150 ⁇ L of urea-phenol red solution was added, and the absorbance was measured at a wavelength of 550nm after shaking, and recorded as the test group data. At the same time, a blank MRS liquid culture medium was used instead of the sample for a control test, which was recorded as the control group data. The above experiment was repeated 3 times, and the results were expressed as mean ⁇ standard deviation.
  • the urease activity inhibition rate was calculated according to the following formula:
  • Urease activity inhibition rate (%) [(OD control group - OD test group) / OD control group] ⁇ 100
  • mice A total of 56 6-week-old SPF-grade C57BL/6 male mice were purchased from Zhubai Baishitong Biotechnology Co., Ltd. for animal experiments on the prevention of Helicobacter pylori infection by Lactobacillus gasseri TF08-1 probiotics and postbiotics. The experiment was divided into 4 groups. The experimental groups and intervention methods are shown in Table 1:
  • the infection dose of Helicobacter pylori liquid was 100 million CFU/day/mouse, and the mice were gavaged every other day for a total of 5 times to infect with Helicobacter pylori.
  • the mice were dissected, and the serum TNF- ⁇ , IL-1 ⁇ , IL-6 and IL-10 levels were determined using the corresponding Elisa detection kits.
  • the gastric Hp load was counted using GSSA-Hp selective Columbia blood agar plates, and the gastric tissue was subjected to histopathological analysis using HE staining.
  • the pathological sections were scored according to the severity of five indicators, including the number of Hp, activity, chronic inflammatory response, atrophy, and intestinal metaplasia area (normal: 0 points, mild: 1 point, moderate: 2 points, and severe: 3 points).
  • the experimental results are shown in Figures 1 and 2.
  • the "*” in the charts indicates that there is a difference between the intervention group and the model control group. (p ⁇ 0.05), “**” indicates that the intervention group is significantly different from the model control group (p ⁇ 0.01), and “***” indicates that the intervention group is extremely significantly different from the model control group (p ⁇ 0.001).
  • the experimental results show that compared with the normal control group, the model control group had Hp infection in the stomach, the load was significantly increased, the levels of pro-inflammatory factors such as serum TNF- ⁇ , IL-1 ⁇ , IL-6 were significantly increased, and the level of anti-inflammatory factor IL-10 was significantly reduced.
  • the gastric tissue pathology analysis score of the model group was 7.17 ⁇ 1.17.
  • the Hp load in the stomach decreased by 94.33% and 84.22% after preventive gavage of Lactobacillus gasseri TF08-1 probiotics and postbiotics, respectively (see Figure 1A for details), and the pathological scores decreased to 4.17 ⁇ 1.60 and 4.83 ⁇ 1.17, with a decrease rate of 41.85% and 32.56%, respectively.
  • the levels of serum proinflammatory factors such as TNF- ⁇ , IL-1 ⁇ , and IL-6 decreased to varying degrees (see Figures 2A, B, and C for details), and the level of serum anti-inflammatory factor IL-10 increased significantly (see Figure 2D for details).
  • Example 5 Verification of the efficacy of Lactobacillus gasseri TF08-1 in treating Helicobacter pylori infection
  • Hp-infected mice were modeled as follows: first, an antibiotic mixed solution (containing 10 mg/mL ampicillin, 2 mg/mL gentamicin, and 10 mg/mL azithromycin) was gavaged for 3 consecutive days to clear the gastric flora, followed by gavage with Hp bacterial solution at a dose of 100 million/day/mouse, gavage every other day, for a total of 5 times to establish a Helicobacter pylori infection model and verify the model; antibiotic triple therapy included omeprazole 0.12 mg/mL, amoxicillin 6 mg/mL, and clarithromycin 3 mg/mL, twice a day, 0.5 mL each time. After the experiment, experimental indicators such as cytokines, gastric Hp load counts, and gastric tissue sections were measured, and the detection method was the same as in Example 4.
  • an antibiotic mixed solution containing 10 mg/mL ampicillin, 2 mg/mL gentamicin, and 10 mg/mL azithromycin
  • mice after modeling showed an increase in gastric Hp load, gastric tissue damage, increased levels of pro-inflammatory factors such as serum TNF- ⁇ , IL-1 ⁇ , and IL-6, and a decrease in the level of anti-inflammatory factor IL-10.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une utilisation de Lactobacillus gasseri TF08-1 dans la prévention et le traitement d'une infection par Helicobacter pylori. La souche présente l'effet bénéfique d'inhiber la prolifération d'Helicobacter pylori et l'activité uréasique in vitro ; lors d'expérimentations animales, les probiotiques (préparations de bactéries vivantes) et les postbiotiques (préparations de bactéries inactivées) ont pu prévenir et traiter efficacement l'infection par Helicobacter pylori, inhiber la prolifération d'Helicobacter pylori dans l'organisme et améliorer les lésions de la muqueuse gastrique et la réponse inflammatoire systémique causées par l'infection par Helicobacter pylori.
PCT/CN2023/128658 2023-10-31 2023-10-31 Utilisation de lactobacillus gasseri tf08-1 dans la prévention et le traitement d'une infection par helicobacter pylori Pending WO2025091269A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2023/128658 WO2025091269A1 (fr) 2023-10-31 2023-10-31 Utilisation de lactobacillus gasseri tf08-1 dans la prévention et le traitement d'une infection par helicobacter pylori

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2023/128658 WO2025091269A1 (fr) 2023-10-31 2023-10-31 Utilisation de lactobacillus gasseri tf08-1 dans la prévention et le traitement d'une infection par helicobacter pylori

Publications (1)

Publication Number Publication Date
WO2025091269A1 true WO2025091269A1 (fr) 2025-05-08

Family

ID=95583235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/128658 Pending WO2025091269A1 (fr) 2023-10-31 2023-10-31 Utilisation de lactobacillus gasseri tf08-1 dans la prévention et le traitement d'une infection par helicobacter pylori

Country Status (1)

Country Link
WO (1) WO2025091269A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001002578A (ja) * 1999-06-24 2001-01-09 Yasuhiro Koga Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性医薬品
KR20020061040A (ko) * 2001-01-12 2002-07-22 매일유업주식회사 헬리코박터 필로리의 생육을 특이적으로 억제하는 유산균,그 이용방법 및 그를 함유한 제품
CN114561313A (zh) * 2021-08-26 2022-05-31 广州维生君生物科技有限公司 格氏乳杆菌及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001002578A (ja) * 1999-06-24 2001-01-09 Yasuhiro Koga Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性医薬品
KR20020061040A (ko) * 2001-01-12 2002-07-22 매일유업주식회사 헬리코박터 필로리의 생육을 특이적으로 억제하는 유산균,그 이용방법 및 그를 함유한 제품
CN114561313A (zh) * 2021-08-26 2022-05-31 广州维生君生物科技有限公司 格氏乳杆菌及其应用

Similar Documents

Publication Publication Date Title
JP6839329B2 (ja) ヘリコバクター・ピロリ感染症の管理のための組成物
US8092793B2 (en) Treating inflammatory bowel disease with live bacteria
CN117143783B (zh) 一种唾液联合乳杆菌vb330及其应用
CN114259056A (zh) 一种鼠李糖乳酪杆菌在制备用于预防和/或治疗溃疡性结肠炎的食品或药品中的应用
CN108721337B (zh) 一种预防肿瘤化疗肠道毒性的微生物菌剂
JP2011021015A (ja) ヘリコバクター属（Ｈｅｌｉｃｏｂａｃｔｅｒ）により引き起こされる炎症を低下させるための乳酸菌の選択および使用
CN116622572B (zh) 抑制幽门螺杆菌的动物双歧杆菌乳亚种atm-209及其应用
CN111011856A (zh) 用于缓解胃病的组合物、其制备方法及用于缓解胃病的食品
WO2008052468A1 (fr) Nouvelle souche de lactobacillus rhamnosus, composition pharmaceutique la contenant et ses utilisations, et procede de preparation associe
CN114107134A (zh) 一株侧孢短芽孢杆菌及其应用
CN116236511A (zh) 后生元组合物及其在制备抑制幽门螺杆菌的产品中的应用
CN118360221A (zh) 一株卷曲乳杆菌ncu-23及其应用
CN117343880B (zh) 一种唾液宿主关联乳杆菌及其应用
CN115216423A (zh) 一种动物双歧杆菌sf及其在医药和食品中的应用
CN115119940A (zh) 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用
CN117305187A (zh) 一种改善肠道健康状况的乳酸片球菌及其应用
JP2006111573A (ja) バチルス・サブチルス菌株の使用及びその使用に用いられる菌株を含む食品
CN109486732B (zh) 一种长双歧杆菌及其应用
CN120118796A (zh) 一株格氏乳球菌zb15与具有抗炎活性的无细胞发酵冷冻干燥物及其制备方法
WO2025091269A1 (fr) Utilisation de lactobacillus gasseri tf08-1 dans la prévention et le traitement d'une infection par helicobacter pylori
CN116103197B (zh) 一种对幽门螺旋杆菌有抑制作用的嗜热链球菌及其应用
WO2025118641A1 (fr) Akkermansia muciniphila vb202 et son utilisation
RU2247148C2 (ru) Штамм бактерий lactobacillus plantarum p4, штамм бактерий lactobacillus buchneri p0 и препарат-пробиотик на их основе для коррекции дисбактериозов различной этиологии у людей и животных
CN118562689B (zh) 一株抗幽门螺杆菌的凝结魏茨曼氏菌vb320及其应用与培养装置
CN110974822B (zh) 吡咯烷二硫代氨基甲酸铵的制药用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23957146

Country of ref document: EP

Kind code of ref document: A1